Holger Sudhoff

Prof. Holger Sudhoff

Department of Otolaryngology, Head and Neck Surgery, Bielefeld Academic Teaching Hospital Teutoburger Str. 50, 33604 Bielefeld, Germany
Department of Otolaryngology, Head and Neck Surgery, Kopfzen...

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2010 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
TOThorsten Ockermann
Thorsten Ockermann
URUlf Reineke
Ulf Reineke
TUTahwinder Upile
Tahwinder Upile
JEJörg Ebmeyer
Jörg Ebmeyer
HSHolger Sudhoff
Holger Sudhoff

14 October 2009 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
PGPeter Kc Goon
Peter Kc Goon
MSmargaret stanley
margaret stanley
JEJörg Ebmeyer
Jörg Ebmeyer
LSLars Steinsträsser
Lars Steinsträsser
TUTahwinder Upile
Tahwinder Upile
HSHolger Sudhoff
Holger Sudhoff
The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.

12 September 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SSStefanie Schröder
Stefanie Schröder
MLMartin Lehmann
Martin Lehmann
OSOdile Sauzet
Odile Sauzet
JEJörg Ebmeyer
Jörg Ebmeyer
HSHolger Sudhoff
Holger Sudhoff

29 November 2007 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
PGPeter Goon
Peter Goon
CSChris Sonnex
Chris Sonnex
PJPiyush Jani
Piyush Jani
MSMargaret Stanley
Margaret Stanley
HSHolger Sudhoff
Holger Sudhoff
Human papillomaviruses (HPV) infection in benign laryngeal papillomas is well established. The vast majority of recurrent respiratory papillomatosis lesions are due to HPV types 6 and 11. Human papillomaviruses are small non-enveloped viruses (>8 kb), that replicate within the nuclei of infected host cells. Infected host basal cell keratinocytes and papillomas arise from the disordered proliferation of these differentiating keratinocytes. Surgical debulking of papillomas is currently the treatment of choice; newer surgical approaches utilizing microdebriders are replacing laser ablation. Surgery aims to secure an adequate airway and improve and maintain an acceptable quality of voice. Adjuvant treatments currently used include cidofovir, indole-3-carbinol, ribavirin, mumps vaccine, and photodynamic therapy. The recent licensing of prophylactic HPV vaccines is a most interesting development. The low incidence of RRP does pose significant problems in recruitment of sufficient numbers to show statistical significance. Large multi-centre collaborative clinical trials are therefore required. Even so, sufficient clinical follow-up data would take several years.

1 September 2010 in Otology & Neurotology
Verified
Journal Article
Closed access
TOThorsten Ockermann
Thorsten Ockermann
URUlf Reineke
Ulf Reineke
TUTahwinder Upile
Tahwinder Upile
JEJörg Ebmeyer
Jörg Ebmeyer
HSHolger Sudhoff
Holger Sudhoff
Objective: To assess the feasibility and safety of balloon dilation Eustachian tuboplasty (BET) as an option for treatment of patients with Eustachian tube dysfunction. Patients and Interventions: A cadaveric study of 5 temporal human bones was performed. Each bone underwent transnasal balloon dilation Eustachian tuboplasty (BET) with computed tomography and post-dilation histology. The procedure involved the dilation of the cartilaginous and bony portion of the Eustachian tube with a balloon catheter. Results: BET is technically easy to perform. No damage to essential structures, particularly the carotid canal, was found. Conclusion: This newly introduced method seems to be a feasible and safe procedure to dilate the Eustachian tube.

18 November 2015 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
SSStefanie Schröder
Stefanie Schröder
MLMartin Lehmann
Martin Lehmann
JEJörg Ebmeyer
Jörg Ebmeyer
TUTahwinder Upile
Tahwinder Upile
HSHolger Sudhoff
Holger Sudhoff